BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

BioClin Therapeutics, Inc., a privately-­‐held clinical stage drug development company developing a first-­‐in-­‐class anti-­‐FGFR3 (fibroblast growth factor receptor 3) monoclonal antibod...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Estrategias de Negociación con Inversor...

by Foro Capital Pymes

La negociación con inversores es un paso crucial y a menudo intimidan...

Photos Stream